Results
We found that empagliflozin
significantly downregulated the expression of catabolic enzymes (MMP9
and MMP13), and decreased the expression of inflammatory mediators (NO,
PGE2, IL-6, COX2, and INOS), and reduced the cellular senescence level
in IL-1β-treated chondrocytes by inhibiting the nuclear factor kappa-B
(NF-κB) signaling pathway. What’s more, empagliflozin prevented
cartilage degeneration in DMM-induced OA mice model with significant
lower OARSI grade.